Drug Trial Radar · NCT01279967
A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma
Last checked: Nov 19, 2026Latest source record: Nov 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
70
Actual
Start
Jan 2011
Primary completion
Jan 2015
Study completion Mar 2015
Sponsor
- Lead sponsor
- Barts & The London NHS TrustAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cancer Research UK; UK: Barts Center for Experimental Cancer Medicine (CECM) for Trial Coordination
- First posted
- Jan 20, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To examine whether the arginine depleting drug, ADI-PEG 20, might be effective as a targeted therapy in patients with ASS-negative malignant pleural mesothelioma.
Conditions
- Malignant Pleural Mesothelioma
Interventions
ADI-PEG 20Drug
36.8mg/m2 based on BSA, weekly treatment for 6 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- progression-free survivalTime frame: 18 months
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
The Royal Sussex County Hospital
Brighton, United Kingdom
Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital
Cambridge, United Kingdom
Hull and East Yorkshire Hospitals NHS Trust,The Princess Royal Hospital
Hull, United Kingdom
Barts and The London NHS, St Bartholomew's Hospital
London, United Kingdom
Guy's and St Thomas' Foundation Trust, Guy's Hospital
London, United Kingdom
University Hospital of South Manchester NHS Foundation Trust, Wythenshawe Hospital
Manchester, United Kingdom
Southampton University Hospitals NHS Trust, Southampton General Hospital
Southampton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.